Should You Buy Halozyme Therapeutics Inc (HALO) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
BUY now for a beginner long-term investor with $50k–$100k. HALO just raised 2026 revenue guidance (23%–30% YoY implied) and the stock is showing strong fundamental momentum. While the chart is near a short-term resistance zone and hedge funds have been net sellers, options positioning and the company’s accelerating revenue/earnings trend support owning shares now rather than waiting for a perfect entry.
Technical Analysis
Price closed at 72.801 (+3.72%), moving up toward near-term resistance.
- Trend/levels: Pivot 71.362. Price is above pivot (constructive), with resistance at R1 73.36 then R2 74.594; support at S1 69.364 then S2 68.13.
- Momentum: RSI(6)=64.543 (neutral-to-slightly warm, not overbought). MACD histogram -0.202 and negatively contracting (downtrend pressure is fading, but not a confirmed bullish MACD turn yet).
- Moving averages: Converging MAs suggest consolidation/transition rather than a clean trend.
- Pattern stats provided: Similar-pattern projection suggests modest near-term upside bias (next week +5.63% median outcome), though next-day is mixed.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Bottom line technically: bullish continuation is possible if HALO holds above ~71 and breaks/holds above ~73.4; otherwise expect consolidation with key downside levels ~69–68.
Analyst Ratings and Price Target Trends
Recent trend: mixed but generally constructive—multiple bullish firms raised targets, while Goldman turned notably bearish.
- Bullish: TD Cowen raised PT to $90 (Buy); Citizens JMP raised PT to $92 (Outperform); Morgan Stanley kept Overweight though trimmed PT to $75.
- Bearish: Goldman downgraded to Sell with $56 PT, citing a significant post-2030 Enhanze royalty cliff risk.
Wall Street pros vs cons:
- Pros: strong quarter execution, expanding partnered products/royalty stream, and a credible path to high EBITDA levels (bull case supports ~$90+ targets).
- Cons: longer-dated durability/terminal value questions around royalties after 2030 and whether BD/acquisitions can offset roll-offs (bear case supports ~$56).
Other flows/people: Insiders are neutral recently; no recent Congress trading data available.
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 78 USD with a low forecast of 56 USD and a high forecast of 92 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 78 USD with a low forecast of 56 USD and a high forecast of 92 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 72.830
Current: 72.830
